AllRock Bio Bets on Combination Strategy in Crowded Pulmonary Hypertension Field

NATICK, Mass. – April 09, 2026 – AllRock Bio, a clinical-stage biotechnology company, has dosed the first patients in a crucial Phase 2a trial for its novel drug, ROC-101, marking a new entry into the fiercely competitive and rapidly evolving landscape of pulmonary hypertension treatment. The study, dubbed ROCSTAR, will evaluate the oral, once-daily pan-ROCK inhibitor in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (ILD-PH), two severe and life-threatening conditions.

The trial's design reveals a shrewd strategy: it will not only test ROC-101 as an add-on to standard therapies but includes a specific arm for patients already being treated with sotatercept (Winrevair), the recently approved blockbuster from Merck that has already begun to reshape treatment paradigms. This positions ROC-101 not as a direct competitor, but as a potential partner to the new standard of care, aiming to push patient outcomes beyond what either drug can achieve alone.

A New Strategy in a Shifting Landscape

The world of PAH treatment has been fundamentally altered by the recent approval of sotatercept. Unlike older therapies that primarily focus on dilating blood vessels for symptomatic relief, sotatercept is a first-in-class activin signaling inhibitor that targets the underlying vascular remodeling, a key driver of the disease. Data from its pivotal STELLAR trial showed an 84% lower risk of death or clinical worsening, setting a new and formidable benchmark for efficacy.

In this new environment, AllRock Bio's approach with the ROCSTAR trial is particularly noteworthy. By designing a study that embraces combination therapy with sotatercept from the outset, the company is acknowledging the new treatment reality. The strategy hinges on the idea of complementary mechanisms. While sotatercept rebalances growth signaling pathways to reverse vascular remodeling, ROC-101 takes a different route, targeting the inflammatory, proliferative, and fibrotic processes through a mechanism known as pan-ROCK inhibition. The hope is that attacking the disease from two distinct, powerful angles could produce a synergistic effect, offering deeper and more durable benefits for patients who still have a high unmet need, even on the latest therapies.

"We have successfully dosed our first patients with ROC-101, including in combination with a stable dose of sotatercept," said Dr. Kate Steiner, VP and Head of Clinical Development at AllRock, in the company's announcement. "We believe ROC-101, with its oral, once-daily dosing, has differentiated potential to address underlying disease mechanisms, further reduce pulmonary vascular resistance and improve functional outcomes for patients on top of existing therapies."

Targeting the Roots of the Disease

For decades, PAH treatments have centered on three main pathways—prostacyclin, nitric oxide, and endothelin—all of which primarily induce vasodilation. While life-extending, these drugs have limited impact on the progressive thickening and stiffening of the pulmonary artery walls. ROC-101 represents a newer wave of therapies aiming to modify the disease at its source.

The drug is a potent, selective inhibitor of both rho-associated protein kinase 1 (ROCK1) and ROCK2. These enzymes are key drivers of cellular processes that go haywire in PAH and ILD-PH, contributing to vasoconstriction, inflammation, fibrosis, and the pathological proliferation of smooth muscle cells that narrows blood vessels. By inhibiting both isoforms, ROC-101 aims to deliver a comprehensive blockade of these disease pathways. This pan-ROCK inhibition has long been a target of interest, with earlier drugs like fasudil showing proof-of-concept in Asia, but ROC-101 represents a modern, oral formulation developed for the global stage.

A critical advantage highlighted from its Phase 1 study in healthy volunteers is its safety profile. The drug was found to be safe and well-tolerated, importantly showing no evidence of hypotension (low blood pressure), a common side effect of vasodilating drugs that can limit dosing and efficacy. This clean safety profile was a key factor in securing the company's $50 million Series A financing and provides a wider therapeutic window as it moves into patient studies.

The Promise for Patients with Severe Lung Disease

PAH is a rare but devastating disease, affecting an estimated 192,000 people globally and leading to 22,000 deaths in 2021. Despite a growing number of approved drugs, the median survival is still only about seven years post-diagnosis. The disease causes dangerously high blood pressure in the arteries of the lungs, putting immense strain on the right side of the heart, which can eventually lead to heart failure. Patients often suffer from severe shortness of breath, fatigue, and diminished ability to perform daily activities. The burden is even higher for those with ILD-PH, where pulmonary hypertension complicates an underlying progressive lung-scarring disease, leading to worse outcomes and very limited treatment options.

For these patients, the ROCSTAR trial represents a new beacon of hope. The prospect of an oral, once-daily pill that could not only manage symptoms but potentially halt or reverse the underlying disease process is a significant leap forward. Many existing effective therapies, such as prostacyclins, can require burdensome continuous intravenous or subcutaneous infusions, dramatically impacting a patient's quality of life. The convenience of ROC-101, combined with its novel mechanism, could make it a highly attractive option for both patients and clinicians. The trial will enroll up to 40 patients with WHO functional class II and III disease, measuring the change in pulmonary vascular resistance at 24 weeks as its primary goal.

AllRock's Experienced Team and Strategic Backing

While AllRock Bio is a relatively new name, the team behind it brings a wealth of experience and a track record of success. The company's leadership includes several key executives from the former CinCor Pharma, a biotech that was successfully acquired by AstraZeneca for up to $1.8 billion in 2023. CEO Catherine Pearce and CBO Justin Thompson, both founders of AllRock, were instrumental in CinCor's journey from formation to its high-profile acquisition.

This seasoned leadership was crucial in securing a substantial $50 million Series A financing round co-led by top-tier venture firms Versant Ventures and Westlake BioPartners. The funding is intended to see the ROCSTAR trial through to completion. The asset itself, ROC-101, was exclusively licensed from Sanofi, which had acquired it through its purchase of Kadmon in 2021.

This combination of an experienced management team, strong financial backing, and a promising clinical asset positions AllRock Bio as a serious contender. The company's strategy appears clear: leverage a novel, de-risked asset to quickly generate compelling human proof-of-concept data in a high-value indication. By smartly designing its trial to demonstrate value in the post-sotatercept era, AllRock is not just developing a drug; it is carving out a specific and potentially lucrative niche in the future of cardiopulmonary medicine. The results of the ROCSTAR trial will be eagerly awaited by investors, clinicians, and patients alike.